Wedbush Research Analysts Raise Earnings Estimates for STOK

Stoke Therapeutics, Inc. (NASDAQ:STOK) – Research analysts at Wedbush lifted their Q1 2025 earnings per share estimates for Stoke Therapeutics in a research note issued on Tuesday, January 7th. Wedbush analyst L. Chico now anticipates that the company will post earnings per share of ($0.56) for the quarter, up from their previous estimate of ($0.59). The consensus estimate for Stoke Therapeutics’ current full-year earnings is ($2.03) per share. Wedbush also issued estimates for Stoke Therapeutics’ Q2 2025 earnings at ($0.49) EPS, Q3 2025 earnings at ($0.51) EPS, Q4 2025 earnings at ($0.52) EPS, FY2025 earnings at ($2.08) EPS, FY2026 earnings at ($2.32) EPS, FY2027 earnings at ($2.53) EPS and FY2028 earnings at ($2.27) EPS.

A number of other research analysts have also issued reports on STOK. Needham & Company LLC reiterated a “buy” rating and set a $22.00 price target on shares of Stoke Therapeutics in a research note on Wednesday. Leerink Partnrs upgraded shares of Stoke Therapeutics to a “strong-buy” rating in a research report on Friday, October 11th. Cantor Fitzgerald reissued an “overweight” rating on shares of Stoke Therapeutics in a report on Tuesday, December 10th. HC Wainwright reiterated a “buy” rating and set a $35.00 price target on shares of Stoke Therapeutics in a research report on Wednesday. Finally, Leerink Partners began coverage on shares of Stoke Therapeutics in a research report on Monday, October 14th. They set an “outperform” rating and a $18.00 target price for the company. One equities research analyst has rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Stoke Therapeutics presently has an average rating of “Buy” and an average target price of $21.29.

Stoke Therapeutics Stock Down 3.8 %

STOK opened at $8.96 on Friday. The company has a market cap of $474.58 million, a PE ratio of -4.27 and a beta of 0.95. The business has a 50 day moving average price of $11.98 and a two-hundred day moving average price of $13.08. Stoke Therapeutics has a 52 week low of $4.09 and a 52 week high of $17.58.

Stoke Therapeutics (NASDAQ:STOK) last posted its quarterly earnings results on Tuesday, November 5th. The company reported ($0.47) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.05. Stoke Therapeutics had a negative return on equity of 54.45% and a negative net margin of 629.90%. The company had revenue of $4.89 million for the quarter, compared to analysts’ expectations of $3.46 million.

Insiders Place Their Bets

In other news, CEO Edward M. Md Kaye sold 6,786 shares of the firm’s stock in a transaction on Monday, December 9th. The shares were sold at an average price of $12.99, for a total value of $88,150.14. Following the sale, the chief executive officer now owns 61,885 shares in the company, valued at approximately $803,886.15. This trade represents a 9.88 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Barry Ticho sold 2,586 shares of Stoke Therapeutics stock in a transaction dated Monday, December 9th. The stock was sold at an average price of $12.99, for a total value of $33,592.14. Following the sale, the insider now directly owns 44,746 shares in the company, valued at approximately $581,250.54. This trade represents a 5.46 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 62,849 shares of company stock worth $809,421 in the last quarter. 11.30% of the stock is currently owned by corporate insiders.

Institutional Trading of Stoke Therapeutics

Several hedge funds have recently modified their holdings of the stock. Lynx1 Capital Management LP lifted its stake in shares of Stoke Therapeutics by 40.3% in the 2nd quarter. Lynx1 Capital Management LP now owns 5,185,191 shares of the company’s stock valued at $70,052,000 after purchasing an additional 1,488,371 shares during the period. RTW Investments LP grew its position in shares of Stoke Therapeutics by 10.1% during the 3rd quarter. RTW Investments LP now owns 4,652,285 shares of the company’s stock worth $57,177,000 after buying an additional 427,447 shares during the period. State Street Corp increased its stake in shares of Stoke Therapeutics by 8.6% in the 3rd quarter. State Street Corp now owns 1,728,888 shares of the company’s stock valued at $21,248,000 after acquiring an additional 137,145 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund boosted its stake in Stoke Therapeutics by 426.1% during the 2nd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 1,387,200 shares of the company’s stock worth $18,741,000 after acquiring an additional 1,123,500 shares during the last quarter. Finally, Marshall Wace LLP increased its stake in Stoke Therapeutics by 550.1% in the second quarter. Marshall Wace LLP now owns 1,161,037 shares of the company’s stock valued at $15,686,000 after purchasing an additional 982,451 shares in the last quarter.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.